Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 11/20 | 0.39 |
| ▸ | SLC16A1 | P53985 | 10/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126098 | 0.89 | NAMPT (0.39) | SLC16A3SLC16A1HTTCNR1HSD11B1 | |
| SCHEMBL3705041 | 0.89 | SLC16A3 (0.39) | SLC16A3SLC16A1CNR1PDE4B | |
| SCHEMBL3701580 | 0.87 | HTR2C (0.44) | SLC16A3SLC16A1 | |
| SCHEMBL4126819 | 0.87 | CNR1 (0.38) | SLC16A3SLC16A1CNR1HSD11B1CYP2C9 | |
| SCHEMBL3696956 | 0.86 | SLC16A3 (0.40) | SLC16A3SLC16A1SMN1; SMN2 | |
| SCHEMBL4126573 | 0.86 | SLC16A3 (0.46) | SLC16A3SLC16A1CNR1 | |
| SCHEMBL3701584 | 0.86 | SLC16A3 (0.39) | SLC16A3SLC16A1PDE4B | |
| SCHEMBL3699218 | 0.85 | SLC16A3 (0.36) | SLC16A3SLC16A1CNR1 | |
| SCHEMBL3702449 | 0.85 | ALDH1A1 (0.44) | SLC16A3SLC16A1CNR1SMN1; SMN2CYP2C9 | |
| SCHEMBL4135860 | 0.85 | SLC16A3 (0.37) | SLC16A3SLC16A1CNR1PDE4BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190822-B1 | 5-MEMBERED HETEROCYCLIC COMPOUNDS AS PROTON PUMP INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-20090156642-A1 | 5-Membered heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156642-A1 | 5-Membered heterocyclic compound | CEL, PGA5, COG5 | SLC16A3 2809/4885SLC16A1 2925/4885HTT 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.